Issued 2026-08-13 at $3.29 · now $3.31 (2026-08-13, +0.6% since)
Based on its own history, a month from the 2026-08-13 close, RXRX has typically landed between $2.29 and $4.73 — a range of −30.4% to +43.6% from the issuance price $3.29.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,316 overlapping 1 month windows · 2021-04-15 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($3.29) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where RXRX has typically landed a month from the 2026-08-13 close of $3.29 — the range is history, not a prediction.
- now $3.31 (+0.6%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $3.14 (-4.7%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.7–$3.57
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.29–$4.73
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2022-02-11 | −47.9% | −48.6% | +0.0% |
| 2022-02-10 | −47.8% | −47.8% | +1.7% |
| 2021-07-21 | −46.8% | −47.1% | +0.0% |
| 3 best | |||
| 2023-05-02 | +92.3% | +0.0% | +102.9% |
| 2023-06-22 | +90.1% | −14.5% | +105.7% |
| 2023-05-12 | +87.9% | −3.0% | +87.9% |
1,316 overlapping windows · 2021-04-15 – 2026-08-13 · not cherry-picked
Pending catalysts
- June 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) (source, as of 2026-08-14)
- 2028-10-30 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.